Fly News Breaks for May 19, 2016
MRK
May 19, 2016 | 08:46 EDT
BMO Capital believes that data released at ASCO indicates that Merck's (MRK) Keytruda, in combination with Bristol-Myers Squibb's (BMY) Opdivo, will become the new standard of care in PD-L1 positive 1L NSCLC patients. The firm thinks that Keytruda is "becoming more competitive" in 1L NSCLC.
News For MRK From the Last 2 Days
There are no results for your query MRK